MedImmune Spins Out Viela Bio to Develop Six Candidates, Two Ophthalmic

March 2, 2018: By Joan McKenna

AstraZeneca’s MedImmune subsidiary has spun out six programs, including two ophthalmic, into a new startup called Viela Bio.

Gaithersburg, Maryland-based MedImmune is a biologics research and development subsidiary of UK-based AstraZeneca.

Viela Bio also will be located in Gaithersburg.

Viela Bio will focus on severe autoimmune diseases. Clinical candidates include inebilizumab, currently in Phase II development for neuromyelitis optica, a rare condition that affects the optic nerve and spinal cord.

The company also is developing prezalumab, in a Phase IIa study for primary Sjogren syndrome.

Viela Bio will be an independent company. It is being funded with up to $250 million from a group of investors led by Boyu Capital, 6 Dimensions Capital, and Hillhouse Capital. Other participants include Temasek and Sirona Capital. AstraZeneca will be the largest minority shareholder.

Bing Yao, PhD, formerly head of MedImmune’s Respiratory, Inflammation and Autoimmunity Innovative Medicines unit, is Viela’s first chief executive officer.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Aerie Submits NDA for Roclatan to US FDA

Surface Raises $20 Million in Series A Financing from Flying L Partners

iSTAR Announces ‘Promising’ Early-Stage Results for MINIject MIGS Device

Carl Zeiss Meditec Revenues Total $723.8 Million in the First Half of FY2018, a 4.5 Percent Increase

Moorfields Team Develops Drink-Based Dye for Diagnosing Retinal Disease in Children

Supreme Court Upholds Inter Partes Review Process for Challenging Patents

Study Indicates Ophthalmology Residents Face High Burden of Burnout, Depression

Takeda Makes Firm $62.2 Billion Bid for Shire

Valeant to Rebrand as Bausch Health Companies in July

Hoya Receives CE Mark for Vivinex IOL with 4-in-1 MultiSert Preloaded Delivery System

Tilganga Institute of Ophthalmology Gets $930 Thousand Grant to Double IOL Production

Abpro Postpones $60 Million IPO; Company Has Anti-VEGF/ANG-2 Product Candidate

Valeant Reports Q1-2018 Revenues of $1.9 Billion, a Decline of 5 Percent

Glaukos’ Net Sales Grow 12 Percent in Q1-2018

Second Sight Reports 16 Argus II Implants in Q1-2018

Omeros’ Omidria Revenues Drop 86 Percent in Q1-2018; Company Attributes Decline to Temporary Loss of Pass-through Status

Bausch + Lomb Starts Clinical Trial for New Ophthalmic Viscosurgical Device

NEI Awards LayerBio $1.2 Million to Develop Sustained-Release Glaucoma Drug

Bausch + Lomb Launches Lumify, OTC Eye Drop with Low-Dose Brimonidine for Ocular Redness

Aerie Launches Rhopressa in US as Treatment for Lowering IOP

Coming soon

2018 Cataract Surgical Equipment Report: A Global Market Analysis for 2017 to 2023